New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment
SINGAPORE – Media OutReach – 28 June 2023 – Biosyngen, an immuno-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, today announced the official opening of its latest Good Manufacturing Practice (GMP) facility in Singapore. The facility will support cell manufacturing for immunotherapies in Singapore and across the world, and create more than 200 jobs for the cell and gene therapy (CGT) industry in the next three to five years.
